Medoc Ltd., established in 1990, is a leading developer and manufacturer of neuro-diagnostic medical systems used to assess and monitor acute and chronic pain. The company’s products are based on technologies that test and evaluate the function of small and large peripheral sensory nerve fibers – an important value added tool for the burgeoning pain management market.
Diverse product line for multiple applications
The company’s two product lines deliver non-invasive, painless diagnosis and assessment capabilities for research and clinical environments.
The PATHWAY line of pain and sensory evaluation systems offers exciting new applications for advanced pain research and functional MRI studies. The PATHWAY model CHEPS (Contact Heat-Evoked Potential Stimulator) offers a breakthrough in the area of pain-evoked potential, bringing the objective assessment of evoked pain into the clinic and in research laboratories. The system’s protocol enables better understanding of the patient’s pain perception by applying a serious of heat pulses. (Advanced Thermal Stimulator) is being used as a flexible platform in studies and advanced pain research.
Medoc’s Quantitative Sensory Testing (QST) Solutions are widely regarded as the “Gold-Standard” for quantitative assessment of sensory nerve fiber function. The Thermal Sensory Analyzer (TSA-II) is used in the clinical evaluation of small nerve fibers (A-delta & C fibers). The Vibratory Sensory Analyzer (VSA-3000) is used for functional assessment of large peripheral nerve fibers (A-beta).
Sales are made worldwide to private practitioners in Chronic Pain, Neurology and Diabetes in North America, Europe, Asia & the Far East and Israel. Medoc systems have also been selected for use in pilot and multi-center pharmaceutical trials in leading pharmaceutical companies, including Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Sigma Tau, Dainippon and Skye Pharma. Medoc products can be also found in academic and research institutes, such as Massachusetts General Hospital, Johns Hopkins University, Strelitz Diabetes Institute of Eastern Virginia Medical School, Stanford University, National Institutes of Health (NIH), the University of Michigan, Montreal Neurologic Hospital, the Mayo Clinic and many more.
At the forefront of technology
Medoc’s products are based on its successful commercialization of QST techniques and technologies, and integrating them into user-friendly, easy-to-operate, cost-effective systems that can be used in many disciplines. In addition, the company’s patented rapid pain stimulation technology has opened doors for new developments, such as , pharmaceutical research and other pain-related treatments and testing modalities in specific medical and research fields.
Medoc products are creating new clinical pathways for superior management and treatment of pain and pain-related disorders. As the standards-bearer in QST and the emerging applications stemming from its PATHWAY line of Evoked Potential Stimulator solutions, Medoc plays a vital role in new and emerging applications in the pain medicine and research market.
All the company’s products are FDA approved, certified by CSA and are CE marked to EN-60601-1 International Safety Standard.
Medoc’s headquarters are located in Israel, with a U.S. operation office in North Carolina.
Worldwide sales are supported by a sales and service network of international partners in four continents.
Medoc activities in the Israeli market
In 2007, Medoc had decided to expend its activities by exclusively representing international companies and their products in the Israeli market. The company established a new in-house division to manage the new commerce activities in Israel. For additional information (in Hebrew!) about the companies and products we represent in Israel, please visit: www.medoc.co.il